A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
Latest Information Update: 08 Mar 2023
Price :
$35 *
At a glance
- Drugs Interleukin-15 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 10 Aug 2018 Planned End Date changed from 1 Apr 2022 to 1 Jul 2019.
- 26 Jun 2018 Planned End Date changed from 1 Apr 2020 to 1 Apr 2022.